AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05755087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegavivint
Description: Given IV
Study NCT06061406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart visit app
Description: Patients use an obesity-adapted version of aycan's Smartvisit app, which helps track specific behaviors (diet, exercise), query potential problems/complaints, and manage medical documents in a structured way.~A study nurse experienced in the field of nutrition/obesity contacts the patient if necessary and establishes contact with the center physician.
Study NCT05630625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drinking Dashboard
Description: Day-level feedback on alcohol use and consequences
Study NCT05440019 — intervention group
Intervention type: DEVICE
Intervention: IMAGE CAPTURE SESSION
Description: The M3T FERTIGO® is an instrument to be used by a certified gynecologist and in particular by an IVF expert physician in order to observe and monitor the state of the endometrium lining of patients. The M3T device serves as a mini hysteroscope capable of magnification, capturing images and optional image processing thereof. The M3T enables to acquire in-vivo, magnified images of the endometrium surface, to identify key morphological parameters, calculate their attributes and statistics thereof and compare those for different acquisition images and to some standard tissue state tracks. One may then attempt to predict the Embryo transfer optimal timing, based on this analysis.
Study NCT05815082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colorectal cancer resection combined with liver metastasis resection.
Description: The preferred surgical approach is resection of the corresponding colon segment with regional lymph node dissection. If conditions permit, synchronous resection of the primary lesion and liver metastases of colorectal cancer can be performed to achieve curative resection.
Study NCT05815082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal cancer resection combined with liver metastasis resection.
Description: The preferred surgical approach is resection of the corresponding colon segment with regional lymph node dissection. If conditions permit, synchronous resection of the primary lesion and liver metastases of colorectal cancer can be performed to achieve curative resection.
Study NCT05815082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX chemotherapy regimen
Description: Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
Study NCT05900752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: QiMeiYan Probiotics
Description: consume one sachet of the assigned product, once a day after meals.
Study NCT05900752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: consume one sachet of the assigned product, once a day after meals.
Study NCT06410963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reactivate
Description: The study period is 84 days (12 weeks). Depending on the length of the baseline period (randomly assigned to be 7, 14 or 21 days), the treatment period varies between 63-77 days and contains 6-11 sessions. The intervention consists of 2-4 educational sessions in pain mechanisms and fear avoidance and 4-9 sessions of individually tailored intervention with graded exposure and reactivation to avoided physical activities. Intervention will take place from one time per week to one time every two weeks, 30-60 minutes per session. Number of treatment sessions will depend on when the individual participants' goals are considered reached. If necessary, given the participants consent, their legal guardians will be invited to attend the sessions.
Study NCT05056753 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HWBV chair
Description: vibration-actuated, saddle-seat type stool
Study NCT05056753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HWBV chair
Description: vibration-actuated, saddle-seat type stool
Study NCT05539248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN106 20 mg/kg
Description: Induction and maintenance dosing for cohort 1:~12 mg/kg on Day 1, 16 mg/kg on Day 8, and 20 mg/kg on Day 15 and every 4 weeks thereafter;
Study NCT05539248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN106 40 mg/kg
Description: Induction and maintenance dosing for cohort 2:~30 mg/kg on Day 1, and 40mg/kg on Day 8 and every 4 weeks thereafter；
Study NCT05539248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN106 80 mg/kg
Description: Induction and maintenance dosing for cohort 3:~60 mg/kg on day 1, and 80 mg/kg on day 15 and every 8 weeks thereafter.
Study NCT05274334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of de novo lipogenesis non-invasively in exhaled breath
Description: 1. Healthy participants have a good nights sleep whereas they don't eat during the night and until measurements.~2. They come to the lab and make first baseline exhalation sets. An exhalation set consists of 6 exhalations in Mass Spectrometer positive mode and the same in negative mode. One exhalation set takes around 7minutes from start to finish.~3. Participants consume a single oral dose of dose of 70% 2H2O at 2 g/kg body-water.~4. Participants execute several exhalation sets over time.~5. Participants consume 300g of 'Excellence Joghurt Nature gezuckert.~6. Participants execute several exhalation sets over time.~7. After around 4.5hours with regular exhalation sets taking place, the trial is concluded.
Study NCT04956146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib，Sintilimab，Pemetrexed，Carboplatin
Description: Fruquintinib,fruquintinib at the dose determined in phase safety lead-in,5mg-intermittent (2 weeks on/ 1 week off) ，po，every 3 weeks(q3w) ; Sintilimab at the dose 200mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=4\~5，iv，d1；given every 3 weeks (q3w); Maintenance treatment：After 4\~6 cycles of carboplatin treatment, Sintilimab 200mg, iv, d1, q3w；Fruquintinib RP2D intermittent(2 weeks on/1 weeks off), po，q3w； pemetrexed 500mg/m2, d1,iv, q3w until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
Study NCT05560815 — intervention group
Intervention type: PROCEDURE
Intervention: Any surgical procedure
Description: Might differ for substudies.
Study NCT05331950 — intervention group
Intervention type: OTHER
Intervention: Office Workers
Description: Office Workers which will be observed/exposed with different task and different factors
Study NCT05665621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eight-week in-school strength and balance training program
Description: Training program consisting of two 1-hour strength and balance training sessions per week.
Study NCT04863014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evinacumab
Description: Intravenous infusion every 4 weeks (Q4W)
Study NCT04863014 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion Q4W
Study NCT05449613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acupoint application
Description: During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
Study NCT05449613 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
Study NCT04868591 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single session of education and exercise provided by an advanced practice physiotherapist.
Description: In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participant will not receive additional care by the APPT.
Study NCT04868591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple session of education and exercise provided by an advanced practice physiotherapist.
Description: In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participants will receive five additional consultations with the APPT within a 12-week period. During the follow-up visits, the APPT will reassess the participants, provide further education and recommendations, review and modify the home exercise program and may provide other rehabilitation interventions.
Study NCT05890118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara
Description: A commercial formulation of ustekinumab for SC control (0.5mg)
Study NCT05890118 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RT-111 (0.5mg)
Description: RaniPill capsule containing ustekinumab with a dose of 0.5mg
Study NCT05890118 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RT-111 (0.75mg)
Description: RaniPill capsule containing ustekinumab with a dose of 0.75mg
Study NCT04982510 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: complete denture
Description: 3D printed complete denture
Study NCT04982510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: complete denture
Description: 3D printed complete denture
Study NCT04914832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: AZD1222 is a recombinant replication-defective chimpanzee adenovirus vaccine expressing the SARS-CoV-2 S surface glycoprotein.
Study NCT05345886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: Hippotherapy is a rehabilitation method entrusted to a paramedic or medical practitioner who uses the horse in his/her program treatment, in addition to conventional medical care.
Study NCT05007184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chilean Warning Labels
Description: These labels were implemented in Chile in 2016. They are shown on those less-healthy food and beverage products that do not fall within thresholds that are defined for the following nutrients: sugar, sodium, calories and saturated fats. The original labels are in Spanish but the ones that we displayed were in Arabic.
Study NCT05007184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutri-Score Labels
Description: These labels were implemented by the French government in 2017. They are shown on all food and beverage products and range from A to E with the corresponding colours moving from Green to Red (symbolizing best to worst). The scores and grades are calculated based on 7 different nutrients grouped into 2 categories i.e. nutrients to consume (such as fibre) and nutrients to avoid (such as sugar). We modified the labels by adding % sugar per serving on the right side of the labels.
Study NCT05992428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 5mg
Description: \[Part 1\] DA-8010 5mg + Paroxetine 20mg \[Part 2\] DA-8010 5mg + Mirabegron 50mg
Study NCT05992428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine 20mg
Description: \[Part 1\] DA-8010 5mg + Paroxetine 20mg
Study NCT05992428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50mg
Description: \[Part 2\] DA-8010 5mg + Mirabegron 50mg
Study NCT06400108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dementia Moves
Description: Dementia Moves: Dementia Moves is a multicomponent exercise program that can be individually tailored to the abilities of LTC residents with more advanced dementia and focuses on moderate- to high-intensity strength and balance activities with an aim to improve ADLs. Individualized strategies are implemented throughout the intervention to support and promote participation of individuals with more advanced dementia.~Each exercise will be individually prescribed for each participant by the physiotherapists (PT) at the beginning of the program. The intensity of the exercise will be adjusted throughout the program by the PT to ensure the target intensity of moderate to high intensity balance and strength exercises. The intervention will be provided face to face in groups of 4 residents with the PT, PTA, and three volunteers. Though the intervention is delivered in a group setting, the specific exercises that the participants complete are individualized based on their abilities.
Study NCT06106451 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care plus Enhanced Patient Education
Description: Patients in this arm will receive a pamphlet explaining the benefits of cardiac rehabilitation. This pamphlet will be given in addition to standard of care patient education. The research team will also call the patient at four specified time points to provide additional information.
Study NCT06106451 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing Intervention
Description: Patients in this arm of the study will participate in a tailor-made motivational interviewing program. These motivational interviewing sessions will focus on enhancing communication with patients. Each motivational interviewing session will be approximately one hour long. There will be a total of 4-6 motivational interviewing sessions.
Study NCT06106451 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Activity Program plus Motivational Interviewing Intervention
Description: Patients in this arm will be evaluated on postoperative day 1 by a physical therapist on the study team. After the evaluation, the physical therapist will use the information from the evaluation to make a tailored home-based physical activity program for the patient. The patient will begin the home-based physical activity program on the day of their 1-month post-operative cardiology clinic appointment. In addition to the home-based activity program, patients will participate in a tailor-made motivational interviewing program. These motivational interviewing sessions will focus on enhancing communication with patients. Each motivational interviewing session will be approximately one hour long. There will be a total of 4-6 motivational interviewing sessions.
Study NCT05295654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinect validation
Description: Participants will perform several movements while both the vicon and kinect are measuring.
Study NCT05768659 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fear Conditioning
Description: It is a 2-day paradigm. Participants will undergo an auditory fear conditioning task in 3 phases: (1) pre-conditioning habituation, (2) unconditioned stimulus (US) calibration, where USs will be delivered to set the individual stimulation intensity threshold, and (3) fear conditioning, in which participants will be exposed to the conditioned stimulus (CS) associated with the US with an 80% pairing rate. 24 hours later, the (1) implicit recognition of the CS and novel stimuli (NSs), and the (2) explicit recognition, through an alternative forced-choice task will be assessed. Also, (3) the perceptual discrimination (among the CS and NSs) will be tested.~Event-related skin conductance responses (SCRs) will be collected as an implicit index of defensive fear responses, while the accuracy in detecting and discriminating the CS from NSs as the explicit index. Psychological questionnaires about anxiety symptoms will be also administered.
Study NCT05909566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Description: Education to front line clinicians and staff on standardized implementation and weaning of HHFNC and standardized assessments of patient work of breathing. HHFNC implementation and weaning strategies will be based on age-specific practices recommended by the American Academy of Pediatrics. Education will be undertaken by dedicated clinical educators.
Study NCT05909566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Decision Support (CDS)
Description: Education to front line clinicians and staff on standardized implementation and weaning of HHFNC and standardized assessments of patient work of breathing. HHFNC implementation and weaning strategies will be based on age-specific practices recommended by the American Academy of Pediatrics. Education will be undertaken by dedicated clinical educators.
Study NCT05909566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HHFNC Weaning
Description: Wean patient off oxygen and flow as oxygenation and work of breathing improves.
Study NCT05909566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HHFNC Weaning
Description: Wean patient off oxygen and flow as oxygenation and work of breathing improves.
Study NCT05470933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ01075
Description: Phase Ia: Dose Escalation Accelerated titration (the first two dose groups) and 3 + 3 combination (the subsequent dose group) were used for dose escalation.~Phase Ib: Dose Expansion and Cohort Expansion The actual dose, dosing schedule (including combination) and indication selection will be evaluated based on the results of existing trials.
Study NCT05924906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB002
Description: Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion
Study NCT05544864 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Drug eluting stent (DES)
Description: DES-implantation with an everolimus-eluting stent (Xience, Abbott Vascular)
Study NCT05544864 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Drug coated ballloon (DCB)
Description: DCB angioplasty with any commercially available drug-coated balloon
Study NCT06207123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-118
Description: LP-118 is an experimental anti-cancer drug that is currently being studied in clinical trials for multiple types of hematological cancers and solid tumors.
Study NCT06207123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib is used to treat certain types of chronic myeloid leukemia (CML; a type of cancer of the white blood cells).
Study NCT06207123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine is a chemotherapy medication used to treat various types of cancer, including leukemia, lymphoma, neuroblastoma, and Wilms tumor. Vincristine belongs to the category of vinca alkaloids, a class of drugs that function by impeding the proper division of cancer cells.
Study NCT06207123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is used to treat cancer, to decrease inflammation and sometimes used before and after chemotherapy to prevent or treat nausea and/or vomiting. It is given in the vein (IV) or orally (by mouth)
Study NCT06207123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate is a drug used to treat cancer of the blood, bone, lung, breast, head, and neck. It can also treat rheumatoid arthritis and psoriasis.
Study NCT04780581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 6 mg/24h - 10 days
Study NCT04780581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 250 mg/ 24h - 3 days
Study NCT04985799 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gynecare TVT Exact Continence System
Description: Participants will have placement of Gynecare TVT Exact sling.
Study NCT05745623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-723
Description: ICP-723 tablet administered orally，once a day，for every 28 days as one cycle
Study NCT05728502 — intervention group
Intervention type: DRUG
Intervention: Vericiguat (Verquvo, BAY1021189)
Description: Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
Study NCT05728502 — intervention group
Intervention type: DRUG
Intervention: Standard of Care (SoC)
Description: Dosage at the discretion of the treating physician.
Study NCT05852691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig
Description: Participants will receive intravenous (IV) tobemstomig every 3 weeks (Q3W) until disease progression or until up to 24 months after the first treatment, whichever is sooner.
Study NCT05852691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Participants will receive IV pembrolizumab Q3W until disease progression or until up to 24 months after the first treatment, whichever is sooner.
Study NCT05852691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
Study NCT05852691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
Study NCT05679323 — intervention group
Intervention type: OTHER
Intervention: KATZ index of independence in activities of daily living
Description: KATZ index measures self-care tasks using a dichotomous rating (dependent-0/independent-1) including; bathing, dressing, toileting, transferring to and from a chair, maintaining continence, and feeding. Six points are considered independent and 0 points are considered fully dependent. Assessment of each patient is made through a phone call at day 1, 3 and 5 after discharge